Insider Transactions Reported by 21 Insiders of Quince Therapeutics, Inc.

Symbol
QNCX on Nasdaq
Location
South San Francisco, CA

Insiders trading volume in the past year

Quince Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Dirk Thye CEO and CMO, Director $1,690,274 10 Dec 2025
Philip S. Low Director $488,126 19 May 2022
Brendan Hannah Cbo, Coo & Cco $344,834 05 Dec 2025
CHRISTOPHER P. LOWE Interim CEO, COO & CFO $249,100 03 Mar 2022
Charles S. Ryan President $156,953 18 Jun 2025
Leslie Holsinger EVP, Preclinical Development $139,195 06 Jun 2022
Benatti Luca Director $135,951 -$173,500 -56% 26 Dec 2025
Michael J. Detke Chief Medical Officer $131,600 03 Mar 2022
Caryn Gordon McDowell Chief Legal & Adm. Officer $115,150 06 Jun 2022
Ted Monohon Chief Accounting Officer & VP $25,794 06 Mar 2023
Guenter Janhofer Chief Scientific Officer $14,108 23 Oct 2023
Marwan Sabbagh Director 14 Mar 2022
Casey Lynch Chief Executive Officer, Director 03 Jan 2022
Stephen S. Dominy Chief Scientific Officer, Director 03 Jan 2022
Karen L. Smith Chief Medical Officer 01 Feb 2023
UNA S. RYAN Director 04 Jun 2025
Christopher J. Senner Director 04 Jun 2025
David Lamond Director 04 Jun 2025
Margaret McLoughlin Director 04 Jun 2025
June Bray Director 04 Jun 2025
Rajiv Patni Director 04 Jun 2025

Recent Insider Transactions by Companies or Individuals for Quince Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.